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Summary
Cells acquire their ultimate identities by activating combinations of transcription factors that 
initiate and sustain expression of the appropriate cell-type specific genes. T-cell development 
depends on the progression of progenitor cells through three major phases associated with distinct 
transcription factor ensembles that control their recruitment to and proliferation in the thymus, 
their lineage commitment, and their responsiveness to T-cell receptor (TCR) signals, before the 
allocation of cells to particular effector programs. All three phases are essential for proper T cell 
development, as are the mechanisms that determine the boundaries between each phase: cells 
failing to shut off one set of regulators before the next gene network phase is activated are 
predisposed to leukemic transformation.
Introduction
The T-cell developmental program, initiated and sustained by the unique thymic 
environment, guides small numbers of pluripotent cells through multiple rounds of 
proliferation and differentiation, leading to T-lineage commitment, T-cell receptor (TCR) 
rearrangements, and generation of αβ TCR- or γδ TCR-expressing T-cells that function as 
killers, regulatory cells, or producers of specific cytokines 1-6. In the past five years, the 
transcriptional and epigenetic mechanisms that forge T-cell identity and suppress other 
developmental pathways have come into focus. It is not enough for cells to simply activate 
the set of transcription factors that maintain T-cell gene expression in mature T-cells; 
instead, the developmental program depends on the sequential operation of several distinct 
developmental gene networks.
From the time a lymphoid precursor arrives in the mouse thymus to the first expression of an 
αβTCR, it traverses at least 8 phenotypically distinct stages defined by expression of CD4, 
CD8 and other markers 1-6 — Flt3+ early thymic progenitor (ETP), ETP, double negative 2a 
(DN2a), DN2b, DN3a, DN3b, transitional DN4 and immature single-positive (ISP), and 
double positive (DP) (DN: CD4- CD8-, DP: CD4+ CD8+)(Fig. 1a). Most of these stages 
undergo proliferation, but the degree of proliferation and the time required to reach the DP 
αβ TCR+ stage vary between lymphoid precursor cohorts. It takes a little over a day for the 
first wave of lymphoid precursors that populate the fetal mouse thymus to generate DN2 
cells (E12.5-E14) and only a total of four days for the first DP cells to appear (E16). In 
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contrast, the lymphoid precursors that continuously trickle into the thymus throughout 
young adult life can take ten days to reach DN2 stages and two weeks to develop into DP 
cells, with the extra time providing the opportunity for much more extensive 
proliferation7, 8.
Despite these kinetic differences, the gene expression patterns at given developmental stages 
of fetal and adult thymocytes are similar9. This similarity extends to the transcription factor 
genes that are characteristically expressed at each stage (Fig. 1b) as well as to the 
differentiation genes that these factors regulate. Thus, the transcriptional control of 
proliferation and of developmental progression is to some extent modular and may depend 
upon checkpoints to ensure orderly differentiation. This implies that distinct phases of T-cell 
development are governed not only by key transcription factors, but also by the coordination 
among such transcription factors, synchronized by gene regulatory network connections.
All the events that establish the T-cell identity of precursors are driven by Notch 
signaling10-13. Notch1 molecules on lymphoid precursors interact with Notch ligands in the 
thymic microenvironment, leading to activation of the T-cell-specific developmental 
program. During the first developmental stages, Notch signaling interacts with a “legacy” 
stem and progenitor-cell gene network inherited from multipotent precursors. Both legacy 
genes that will play ongoing roles in T cells and progenitor-specific legacy genes with roles 
confined to the earliest stages participate in this network that we term “phase 1” (Fig. 1b). 
Although still incompletely understood, the phase 1 network may support the extensive 
proliferative expansion of the ETP and DN2a cells, as well as impact upon the order, timing, 
and level of T-cell gene activation. Notch signaling also activates the first T-lineage specific 
transcription factors by its interaction with the phase 1 network, although the newly induced 
factors only express full T cell specification activity under the continuing influence of Notch 
signals in a second phase network.
T-cell specific transcription factors in the phase 2 network mediate commitment-linked 
functions that drive T-cell specific gene expression and open the TCR gene loci for 
rearrangement, as well as repress the expression of the progenitor-cell-specific phase 1 
genes. The phase 2 network thus creates the distinctive T-cell identity. However, this phase 
2 network also must be profoundly modified, once TCR gene rearrangement occurs and 
enables some cells to express either a pre-TCR (TCRβ with invariant pre-TCRα) or a γδ 
TCR. The resulting TCR signal transduction, again under the influence of Notch signaling, 
triggers another regulatory factor network shift, transitioning to phase 3. The phase 3 
network includes newly activated genes that support the T cell phenotype but leads to the 
extinction of the expression of some factors that had played crucial roles in phase 2, reduces 
Notch target gene expression, and enables the cells to become Notch-independent.
The switching between the three phases must be correctly regulated to ensure the fidelity of 
T-cell development and to avoid leukemogenesis. Activation of new regulatory genes and 
repression of those from earlier phases must be accurately coordinated to insure proper 
passage through the developmental checkpoints. An important question is how 
homogeneous the precise trajectory of gene expression changes is between the surface 
receptor-defined stages, and this awaits single-cell transcriptional analysis14. However, a 
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strong relationship has recently emerged between the generation of T-cell leukemias and 
thymocyte precursor competition and self-renewal as well as inappropriate persistence of 
gene expression from the phase 1 restricted genes of normal T-cell development 15-19. This 
relationship provides insights into the origins of certain forms of human T-cell acute 
lymphoblastic leukemias (T-ALL) as well as suggesting the roles of specific stem and 
progenitor cell genes in normal T-cell developmental regulatory networks.
Thus, a three-phase succession of gene networks processes multipotent precursors into T-
lineage committed cells, and sets them on the paths to distinct functional roles. Expression 
of certain individual transcription factors can extend across the boundaries of these phases, 
but their functions in each phase are modulated according to their level and the overall gene 
network state. In this review we explore what these functions are and how they are 
interlinked.
Major features of early T-cell development: a framework
Progenitor interaction with the thymic environment
T-cell progenitors from bone marrow or fetal liver continuously seed the thymus via the 
blood. The major types of prethymic cells that appear competent to do this are multipotent 
precursors: primarily common lymphoid precursors, which express higher levels of the 
interleukin-7 receptor (IL-7R) and lower levels of the receptor tyrosine kinase Kit (CD117), 
and lymphoid-primed multipotent precursors, with lower IL-7R expression but expressing 
high levels of Kit20-23. Whereas the respective contributions of these precursors in vivo is an 
important question, once in the thymus the ETPs derived from them share a Kit-high, IL-7R-
low phenotype and develop into Kit-high, IL-7R-high DN2a cells before commitment. In 
fact, both of the defining growth factor receptors are crucial for early pro-T cell expansion 
within the thymus. Both types of thymic immigrants also express the functionally important 
growth factor receptor Flt3 (FMS-related tyrosine kinase 3; Flk2), as well as Notch124. The 
unique thymic environment not only provides supportive cytokines, Kit ligand and IL-7, 
which maintain and expand the precursors, but it critically provides an environment rich in 
the Notch ligand, Delta-like 4 (DLL4)6. Engagement of Notch1 by environmental Notch 
ligands triggers proteolytic release of intracellular Notch1, which binds to DNA-bound 
RBPJ (or CSL) and recruits a transcriptional co-activator complex to activate Notch target 
genes25.
Stages of early T-cell development
The process of differentation from thymic entry to expression of a full heterodimeric TCR 
can be divided coarsely into Notch-dependent and TCR-dependent parts (Fig. 1a). The early 
cells do not express a TCR, and they proliferate and differentiate in a TCR-independent, 
Notch-dependent fashion. As soon as TCR gene rearrangement yields its first successful 
products, cell survival and differentiation become TCR-dependent, and Notch influence is 
downregulated. For αβ T-cells, TCRβ rearrangement normally occurs in the DN3a stage, 
with TCRα rearrangement delayed until the DP stage. DP αβTCR+ cells then await positive 
selection based on TCR recognition specificity, which is a prerequisite for further 
differentiation into effector T-cell subsets (such as CD4+ T cells, CD8+ T cells, natural 
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killer T cells and regulatory T cells). Rearrangements of both TCRγ and TCRδ, leading to 
γδTCR-expressing cells, take place more synchronously in the DN2 or DN3a stages (Box 1).
A major landmark in the Notch-dependent developmental process is T-lineage commitment, 
which occurs at the DN2a to DN2b transition (Fig. 1a). Commitment marks the final loss of 
factors and gene regulatory networks that allow alternative lineage fate choices under 
permissive conditions4, 26 (Box 2). Under normal conditions in the thymus Notch ligands 
push and retain progenitor cells in the T cell pathway and block alternative fate choices, but 
during commitment the accumulation of Notch-dependent gene regulatory changes makes 
these fates inaccessible regardless of the environment. The commitment transition was 
originally detected with an Lck-GFP transgene27 and is marked in non-transgenic animals by 
a deceptively subtle decrease in Kit expression1, 28. In fact, however, this transition is a 
major gene regulation upheaval which causes both substantial upregulation of many T-cell 
genes and the loss of progenitor-specific gene expression. Dendritic-cell, myeloid, NK 
(ILC1) and probably ILC2 and mast-cell potentials, indicative of sustained diverse and 
permissive regulatory states, are all terminated here4, 26, 29, 30 (Fig. 2). Thus, the Notch-
dependent period of T-cell development is divided into two phases (phase 1: pre-
commitment and phase 2: T-identity), which are profoundly distinct in their transcription 
factor gene network states and developmental properties (Fig. 1b).
By the time commitment has occurred (DN2b–DN3a stages), most T-cell identity genes are 
fully turned on31, 32. Such genes include all of the invariant TCR components and mediators 
of TCR-dependent signaling, the expression of which prepares the cells for TCR-dependent 
survival. Proliferation slows in progression to the DN3a stage, and many cells enter G1 
arrest. The cells of this stage then persist until they successfully rearrange TCR genes, or 
die. Growth and differentiation beyond the β-selection checkpoint at DN3a normally 
requires expression of a functional TCR, which activates the phase 3 gene network. This 
occurs when newly made TCRβ protein assembles at the cell membrane with TCR complex 
components that are already expressed, including pre-TCRα (Ptcra gene product), CD3γ, 
CD3δ, CD3ε and TCRζ. This pre-TCR complex assembly triggers cell enlargement, 
progression into rapid cell-cycling, termination of CD25 (IL-2RA) expression, and increased 
surface expression of CD27 (TNFRSF7) and the co-stimulatory molecule CD28, as the cells 
enter DN3b and then DN4/ISP stages33-37. Although Notch signals are required for passage 
through the β-selection checkpoint38-40, cells responding to this “pre-TCR” then free 
themselves from their Notch-dependence and turn off expression of Notch target genes. A 
somewhat different pathway is followed by cells that productively rearrange the TCRγ and 
TCRδ genes in the DN2-DN3 stages; these become one of a variety of TCRγδ cell types 
(Box1). They too transition from Notch-dependent to Notch-independent differentiation at 
this point.
Critical transcription factors in the induction and establishment of T cell 
regulatory networks
Expression of T-cell differentiation genes and many aspects of mature T-cell function 
eventually depends on a toolkit of transcription factors that includes TCF-1 (Tcf7 gene 
product) and its relative LEF-1, GATA-3, Bcl11b, E2A (Tcf3 gene product) and HEB (Tcf12 
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gene product), Ikaros (Ikzf1, or family members), Myb, Gfi1, and complexes of Runx1 (or 
family members) with CBFβ (Table 1) (see reviews 3, 4, 41-47). The process of T-cell 
programming, through phase 2 and beyond, must establish gene networks that stably 
maintain appropriate levels of these factors. However, these are only part of a much larger 
set of transcription factors that is differentially regulated during the T-cell specification 
process31, 48-50(Fig. 1b)(Table 1).
The induction of critical T cell specification genes such as Tcf7, Gata3 and Bcl11b by 
thymic Notch ligands occurs in the context of previously established legacy stem/progenitor 
cell transcriptional networks. These legacy networks are not immediately dismantled and 
many of these progenitor-specific factors persist through multiple cell cycles and stages 
within the thymus (Figure 1), even though continued expression of these regulatory genes 
beyond the ETP and DN2a stages may be oncogenic. Furthermore, some of these progenitor 
genes are now known to play important roles during the precommitment phase, as described 
below. Understanding what these “phase 1-restricted factors” contribute to normal T-cell 
development is an important frontier in T-cell developmental homeostasis.
Phase 1-restricted transcription factors
Because development of each T-cell precursor cohort is coupled with proliferation, the 
steady-state percentage of thymocytes that are still in precommitment stages is tiny. 
However, in these early stages TCR-independent proliferation from any given immigrant 
can be extensive, spanning more than 10 cell cycles before commitment7, 51, and this 
proliferative expansion could be a major function supported by the legacy progenitor 
network . Many of the transcription factors that are expressed only in phase 1 ETP and/or 
DN2a cells have roles in the proliferation, survival, and self-renewal of other hematopoietic 
cells and leukemias, where the genes that encode them are functionally implicated as proto-
oncogenes (see below; Table 2).
From thymic entry to commitment the cells progress through several variants of the phase 1 
regulatory state, due to the staggered losses of legacy phase 1 restricted genes and gain of 
Notch target genes (Fig. 1b;Fig. 3a-c). The most restricted subset of phase 1 regulators, 
including Gata2, Meis1, and Hoxa9, is expressed solely or predominantly in ETPs. Some of 
these genes may be co-expressed with Flt3 in a pattern restricted to the most primitive ETPs, 
as these genes are known to be involved in regulatory networks in Flt3+ prethymic 
progenitors52, 53. The possibilities for their functions in prethymic progenitors are intriguing, 
but most likely they are important for supporting engraftment in the thymus. Mef2c and 
Lmo2 are turned off a little later, persisting into the DN2a stage, especially in adult 
thymocytes, with their protracted period of expansion31, 32. The phase 1 factors Lmo2, 
Meis1 and N-myc (see below) have a direct connection to “stem-ness”: they have been 
identified recently as potent components of a transcription factor “cocktail” that can 
reprogram differentiated blood cells back to hematopoietic stem cells54.
The most characteristic group of phase 1 transcription factors is expressed throughout the 
precommitment stages. These include Spi1 (PU.1, also called Sfpi1), Hhex, Bcl11a, Gfi1b, 
Erg, Mycn (N-myc) and Lyl1 (and its relative Tal1, expressed at much lower levels)(Figure 
1b; Table 2). Most of these genes are repressed partially or completely during the transition 
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to phase 2 (between DN2a and DN2b), although Lyl1 is only silenced in the DN3a stage28, 
and Erg only during β-selection31, 32.
Bcl11a is crucial for normal lymphoid progenitor proliferative expansion in both fetal liver 
and bone marrow55. Similarly, although the basic helix–loop–helix (bHLH) factor Lyl1 
plays its best-known role in hematopoietic progenitors and B-cells56, 57, deletion of Lyl1 
severely impairs development of lymphoid precursors in bone marrow and specifically 
reduces ETP expansion, progression to DN2, and early T-cell survival56, 58, 59. Lyl1, 
working in dimers with E2A or HEB, probably helps to maintain expression of the crucial 
ETP–DN2 growth factor receptor Kit, similar to the function of the related protein SCL 
(Tal1), and promotes expression of Gfi1, a regulatory factor required for normal generation 
of ETPs and for proper responses to Notch signaling 58, 60, 61. Erg and Hhex are implicated 
in early T-cell self-renewal in both normal and malignant contexts62, 63. Thus, despite their 
transient expression, these factors should be regarded as integral parts of the T-lineage 
program.
PU.1: linking phase 1 and developmental options
PU.1 is normally associated with differentiation of non-T cells, i.e. dendritic, myeloid, and 
B-cells64, and its expression correlates very well with the ability of uncommitted T-cell 
precursors to divert to dendritic cell and myeloid fates when Notch signaling is withdrawn 
(Fig. 2). However, loss of PU.1 from prethymic or DN1 stages also causes an arrest in T-cell 
development65. PU.1 is important for expression of Flt3 in immigrants, and it probably 
sustains the pro-survival actions of Bcl11a in developing thymocytes until they reach 
commitment (phase 2), as well as regulating other phase 1 regulatory genes66. PU.1 is a 
highly stable protein and can act as a pioneer factor in some contexts67-70. It binds to most 
enhancers and promoters active in ETP and DN2a cells in vivo31. Thus, it may in part shape 
the epigenetic landscape in these hematopoietic progenitors in ways that affect the activities 
of many other factors. It may also play a more intimate role in controlling the T-cell 
program, via network interactions with Notch and T-cell commitment genes including Tcf7, 
Myb and Gata366. PU.1 can dampen the intensity of Notch signaling; this contributes to its 
ability to restrain the induction of many T-cell identity genes as long as it is expressed66 (A. 
Champhekar & E.V.R., unpublished results). Because this Notch antagonism is graded and 
not absolute, PU.1 may itself contribute to the proliferative expansion of T-cell precursor 
clones by delaying the onset of commitment, as described below.
Notch target genes in early T cell precursors
Notch signaling activates distinct target genes in disparate developmental contexts, and even 
in DN thymocytes it activates a succession of different target genes at different stages. DN 
thymocytes are primed for responsiveness to intrathymic Delta ligands by expression of 
Fringe proteins encoded by Lfng, Mfng and Rfng71. Notch signaling tightly controls the 
expression of genes encoding the canonical DN2 marker CD25 (Il2ra), the ubiquitination 
adaptor Deltex1 (Dtx1), pre-TCRα (Ptcra), the ankyrin repeat protein Nrarp, Notch3, and to 
some extent Notch1 itself, as well as the transcription factors Myc and Hes1, all of which 
have different patterns of expression in the DN stages39, 72, 73. Notch signaling also strictly 
controls activation of a distinct promoter for Tcf12 (HEB) that drives the expression of a 
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truncated protein, HEBalt, which appears to be more supportive of cell proliferation than 
canonical HEB or E2A46, 74.
Hes1 and Nrarp are among the earliest Notch-activated target genes induced in ETPs. Hes1 
is a bHLH transcriptional repressor that is needed for early T-cell population expansion, and 
may also antagonize myeloid cell development75-77. Nrarp is an adaptor protein that can act 
as a substantial negative feedback regulator of Notch signaling itself78, 79. Whereas Hes1 
expression continues from ETP through the DN3a stage, Nrarp is shut off at commitment. 
Thus in phase 1, Notch signaling is self-limiting and exacerbates the Notch-damping effect 
of PU.1. Both restraints are relieved, however, when the cells undergo commitment. The 
later-activated Notch target genes may thus be awaiting an increase in Notch signal strength 
for their induction as well as other inputs.
Building infrastructure for the Phase 2 network
The regulatory bridge to the phase 2 gene network is built from within the phase 1 network. 
Notch signaling in ETP cells initiates expression of the crucial regulatory genes Gata3 and 
Tcf7 (encoding TCF-1), which then transform the developmental status of the cells (Fig. 3a, 
b). Even in the context of the phase 1 developmental network, these two genes begin to exert 
T-lineage promoting functions as soon as they are expressed, as knockouts of either gene 
severely reduce the survival and differentiation of ETP cells as well as their 
descendants80, 81. They not only begin to antagonize the progenitor-specific, phase 1-
restricted factors (Fig. 3b), but also collaborate with the regulatory genes needed for T cell 
development that were also part of the legacy set, expressed from a prethymic stage (Myb, 
Runx1/CBFβ, Ikaros, Gfi1, E2A). A particularly important member of this group of 
inherited factors is the basic helix-loop-helix factor E2A, which is expressed at relatively 
constant levels throughout T-cell specification, but has its activity substantially modulated 
by availability of different heterodimerization partners45, 46, 58, 82-86. Despite their stable 
expression, all these progenitor-inherited factors can also act in developmentally modulated 
ways, and they become incorporated with TCF-1 and GATA-3 into the network for T-cell 
lineage commitment.
Activation and function of TCF-1
Tcf7 is activated by Notch directly81, 87, but once activated, its expression is no longer 
severely affected by Notch signal inhibition29, 66. This suggests that it may become self-
sustaining by direct or indirect positive feedback (Fig. 3c). In ETPs, TCF-1 drives 
expression of a suite of genes needed for survival and expansion81. Some fetal T-cells can 
develop without it88, 89, but TCF-1 becomes increasingly important in postnatal waves of T-
cell precursors90. TCF-1 primarily acts as a crucial positive regulator of T-cell specification, 
collaborating with Notch to activate T-cell genes through a feed-forward network circuit. 
Although TCF-1 cannot duplicate all effects of Notch signaling, high amounts of a full-
length isoform of TCF-1 can activate many T-cell genes including Gata3, Bcl11b, Il2ra 
(CD25), Cd3g, Lat, Lck and endogenous Tcf7, even without Notch signals87.
It is still controversial whether TCF-1 acts together with β-catenin in these positive 
regulatory roles87, 91. Although it can mediate canonical Wnt signaling via the formation of 
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a complex with β-catenin, TCF-1 may operate in a different mode in ETP and DN2a cells. 
At a later stage TCF-1 can directly or indirectly help to repress Id2, a potent E2A antagonist 
that can otherwise be induced readily in T-cell precursors89. Certain natural isoforms of 
TCF-1 also repress or delay activation of the related TCF-1 gene, Lef1, which can otherwise 
become oncogenic88, 89. Finally, as a highly abundant transcription factor in developing T-
cells, TCF-1 may also play an architectural role at cis-regulatory elements across the 
genome92: its high-mobility group DNA binding domain can bend the DNA to facilitate 
contacts among other transcription factors93.
In prethymic cells the gene encoding TCF-1 (Tcf7) begins with substantial CpG methylation 
on some of its putative regulatory elements94, but its promoter and major enhancer become 
fully active during ETP stage31, and CpG methylation is removed from Tcf7 by the time 
cells reach DN2 and DN3 stages94. This may reflect the action of Notch/RBPJ(CSL) 
complexes at the enhancer, in addition to direct and indirect positive feedback signals from 
TCF-1 and GATA-381, 87. Initially, Notch signals remain important to protect Tcf7 
expression against a variety of experimental regulatory perturbations ranging from excessive 
PU.1 activity66 to excessive GATA-3 activity29. However, in later stages of T-cell 
development (phase 3 and beyond), Tcf7 can be expressed strongly in a Notch-independent 
way, in a pattern often correlated with levels of GATA-3.
GATA-3 functions and regulation
GATA-3 has vital dose-dependent roles in early T-cell survival, growth, specification, and 
commitment, as well as continuing roles in T-cell subset diversification after TCR 
expression and antigen stimulation95, 96. It plays a key non-redundant role in excluding the 
B-cell fate97, and probably explains why B-cell potential is lost within the ETP 
stage24, 98, 99. It is required for full activation of Bcl11b in DN2a-DN2b stage and to prime 
DN3 cells for β-selection, and may also upregulate Ets1 and repress Spi1 in DN2b 
stage29, 97, 100(D. D. Scripture-Adams, S. Damle, and E.V.R., unpublished)(Fig. 3c-e). 
Gata3 expression is activated by a mechanism involving a far downstream enhancer101 and 
by removal of H3K27me3 repression marks from its promoter102, 103, although the 
sequence(s) through which it is activated by Notch in ETP cells have not been identified. 
Part of the regulation of Gata3 could be mediated indirectly, e.g. by TCF-1. Although 
GATA-3 levels can be maintained when Notch signals are removed, Notch signaling is 
needed to enable Gata3 to be expressed in the phase 1 context of high PU.1 activity66.
GATA-3 must be tightly regulated at several levels. First, the negative effect of GATA3 
overexpression on T-cell development is as severe as loss of this transcription factor29, 104. 
In precommitment stages, Gata3 expression can be restrained by phase 1 transcription 
factors PU.1 and Gfi1b66, 105 (Fig. 3a, b). During and after commitment, surprisingly, it is 
restrained by other T-cell specification regulators including E2A and Bcl11b104(Zhang, J.A., 
Li, L., and E.V.R., unpublished data)(Fig. 3d, e). Second, GATA-3 is subject to considerable 
post-transcriptional regulation by signaling pathways that are downstream of many growth 
factor and activation signals, including Akt pathway regulation of its translation and p38 
MAP kinase regulation of its nuclear localization and activity106-108. Thus, GATA-3 activity 
levels in a cell integrate responses to environmental signals with intrinsic transcriptional 
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programming. Third, the sites that GATA-3 binds across the genome are distinct at different 
stages of T cell development, even at matched levels of GATA3 expression. Major 
redistributions of GATA-3 binding are seen between successive DN and DP thymocyte 
stages, as well as between thymocytes and mature T cells31, 109. This is not because 
GATA-3 is particularly excluded by repressed (H3K27me3-marked) chromatin sites, but 
because of shifting preferences among potential open sites. The implication is that GATA-3 
“assignments” depend on interactions with changing stage-dependent collaborating factors. 
Thus, as a member of a regulatory ensemble, this factor may contribute in different ways in 
each of the three phases from ETP to DP stage.
Phase 2 - commitment
Transition to phase 2
Several cell cycles after TCF-1 and GATA-3 are activated, cells transition to the DN2b 
stage, when proliferation rates slow, survival becomes strictly Notch signal-dependent, and 
Kit expression declines28. Bcl11b expression is activated and most phase 1 genes are 
silenced (Fig. 3c-d). As the cells progress through the DN2b stage there are major shifts in 
the expression of Ets family transcription factor genes: Ets1 and Ets2 are sharply turned on 
as Spi1 is turned off48. Lef1 is induced in a highly Notch-dependent way29, 66, adding a 
partially redundant transcriptional regulation activity to that of its relative Tcf788, 89, 110.
During in vitro differentiation, DN2b cells can continue to proliferate, but in vivo these 
transformations presage a faster shift to the DN3a stage. The cells become desensitized to 
IL-7R signaling, in a process dependent on E proteins111. E2A/HEB activity is probably 
boosted by the silencing of the competitor dimer partner Lyl128, 112. E protein and Notch-
dependent gene expression soars (e.g., Rag1, Rag2, Ptcra, Dntt, Cd3e)72, 83, 104, 113-115, and 
as proliferation slows, RAG-mediated TCR gene recombination intensifies (Fig. 3e).
Bcl11b expression is necessary for many if not all of these changes, and the timing of 
Bcl11b activation is crucial for lineage commitment116-118. Bcl11b, a six zinc-finger 
transcription factor with functions including corepressor activity119, is turned on in late 
DN2a. It may repress Kit directly, thus creating the DN2b phenotype; virtually all DN2b 
cells express high levels of Bcl11b (H. Y. Kueh and E.V.R., unpublished results). Both the 
promoter and a far-distant enhancer appear to participate in Bcl11b activation and to contain 
binding sites for Notch, TCF-1, Runx/CBFβ, and possibly GATA-3120, all of which are 
positive regulators for Bcl11b expression87, 97, 118, 121. These known positive regulators are 
expressed before Bcl11b is turned on, but their combined levels may need to exceed a 
threshold in order to remove initial DNA methylation and H3K27me3 marks from both the 
promoter and the enhancer of the Bcl11b gene94, 120.
Commitment: end of progenitor status and other options
The commitment transition from DN2a to DN2b marks the end of a process of exclusion of 
access to different alternative fates (Figure 2). The completion of commitment in DN2b 
stage terminates access to “innate lymphocyte” (NK or ILC1 and ILC2) development28, 30, 
while perhaps surprisingly, potential for non-lymphoid pathways to dendritic cell, 
granulocyte, macrophage and possibly mast-cell development is only extinguished at this 
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point as well (rev. in 26). At least three kinds of molecular mechanisms implement different 
aspects of alternative lineage exclusion, including the repression of PU.1 (Box 2).
The silencing of PU.1 has an obvious link to commitment, but commitment also silences 
many other phase 1 factors such as Gfi1b, Hhex, Bcl11a, Mycn, Lmo2, and Mef2c, which 
have less clear roles in promoting alternative cell fates. Even in some leukemias where these 
factors are aberrantly expressed (see below), they immortalize pro-T cells without obscuring 
their T-lineage identity. This implies that T-cell commitment excludes a progenitor-like 
form of self-renewal as well as specific alternative differentiated fates. Commitment 
mechanisms that silence phase 1 genes are thus most likely to underlie the cell growth 
control alteration that intensifies Notch dependence, slows proliferation, and finally brings 
proliferation under strict TCR dependence28.
The phase 1-specific regulatory genes that are silenced after DN2a show diverse repression 
patterns. The levels of positive enhancer and promoter marks [H3K4me2, H3K(9,14)Ac] on 
these genes are reduced as transcription decreases, but H3K27me3 repression marks 
generally only begin to appear later (if at all), often not until the DP stage31, 103. Bcl11b is 
required for silencing other phase 1 genes during commitment, including Lyl1, Hhex, 
Bcl11a, and possibly Spi1 (PU.1), but it is not yet clear whether Bcl11b directly acts on 
them as a repressor (J. A. Zhang, L. Li and E.V.R., unpublished data)116-118, 122. Thus, a 
variety of negative regulatory mechanisms ensure that phase 1 proto-oncogenes are silent by 
the time cells reach the β-selection checkpoint.
DN3a stage: phase 2 beyond commitment
DN3a stage cells are committed, αβ lineage-biased, and primed for TCR gene rearrangement 
based on a climax of phase 2 regulatory activity. To attain and survive in this stage, cells 
need Runx1/CBFβ, Notch signals, GATA-3, Gfi1, Bcl11b, and E2A; Myb and Ets1 also 
play roles in maintaining viability by this stage if not earlier (Fig. 3e). ChIP-seq analysis 
shows that GATA-3 binding is now redeployed from its phase 1 network targets to a new set 
of target genes31. Some transcription factors, including Ahr and SpiB, are transiently 
expressed only during this DN3a stage (Fig. 1b), but their functions at this point are 
unknown. The maximal expression of the Cd3 gene cluster is regulated by E proteins, 
GATA-3, and TCF-1; the Rag genes are induced by E proteins and GATA-3; and Hes1, 
Notch3, and Ptcra are jointly regulated by E proteins and Notch31, 83, 104, 123, 124.
Involvement of E proteins is a hallmark of gene expression in DN3a cells in particular, and 
E proteins, Notch signaling, and Bcl11b may have a particularly tight collaboration. E 
proteins are needed to promote and sustain Notch1 expression in DN3a cells, and Notch 
signaling can be antagonized by E protein antagonist Id266, 125. Bcl11b may thus support the 
DN3a state by keeping Id2 expression silent117, 118, 122 (Fig. 3d, e). Change in αβ versus γδ 
T-cell potential between the DN2 and DN3a stages could also be related to their differential 
needs for Bcl11b and Notch, as well as the strong activation of Id3 or Id2 factors linked to 
selection of most γδ T-lineages126. The Notch/E protein target gene Ptcra is very poorly 
activated in Bcl11b-knockout cells. αβ T-cells are accordingly disproportionately affected 
by Bcl11b deletion127, 128, whereas several γδ T cell lineages, especially fetal lineages and 
lineages that emerge early from the DN2 stage, are much less affected117, 122, 129, 130. Thus, 
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special features of the DN3a stage may set up the conditions for selection processes specific 
for the αβ T cell lineage.
Phase 3: Crossing the β-selection checkpoint
Construction of the checkpoint
The proliferation and differentiation checkpoint imposed at DN3a is enforced by E2A and 
Ikaros84, 131, 132. There are several clues from target gene analyses that suggest why 
proliferation stops at this point. E2A may slow cell cycling by inducing Cdkn1a123 
(coexpressed with Cdkn2d). Other features of the cells suggest that they are progressively 
starved for growth signals. As they lose support from IL-7R signaling, the cells upregulate a 
PI3-kinase inhibitor, Pik3ip1, and a growth-suppressive kinase, Dapk1, in response to 
E2A104, and these may make the cells dependent on ever-stronger viability support signals 
from Notch and eventually from pre-TCR133. Ikaros, although stably expressed from the 
earliest stages, also has a vital, dose-dependent role in enforcing the β-selection 
checkpoint132, 134. The complexes Ikaros forms are pivotal for patterns of nucleosome 
remodeling activity deployment across the genome135. How exactly Ikaros contributes to 
cell cycle arrest and TCR gene rearrangement is still unclear, but it acts strongly to suppress 
Notch response genes rapidly once pre-TCR signals are received136-138, and this is crucial to 
block leukemogenesis.
β-selection
Signaling through the newly expressed pre-TCR and passage through the β-selection 
checkpoint disrupt the quiescence of DN3a-stage αβ T-cell precursors. Expression of both 
Notch target genes and Il7r is shut off as they move to DN3b and beyond (Fig. 1; Fig. 3f)34. 
Despite the downregulation of these growth-supporting systems, the cells shift into very 
rapid proliferation, as the cells become highly responsive to chemokine signaling through 
the receptor Cxcr4139, 140. Proliferation not only expands the potential TCR repertoire pool, 
it also helps αβ T-cells confirm their lineage commitment by allowing the cells to dilute out 
the last vestiges of earlier regulatory molecules and to reset epigenetic marks37.
Creating the new DP state, the expression of Ets1, Tcf7 (TCF-1), and Lef1 further increases, 
whereas that of Ets2 and Tcf12 (canonical HEB) reaches new peaks. Several new 
transcription factors are turned on during β-selection, including Rorγt, Nfatc3, Pou6f1, and 
Aiolos (Ikzf3), while some like Egr2 and Id3 are transiently activated in response to the 
TCR signal during the rapidly proliferating DN4 stages (Fig. 1). Although E protein activity 
is transiently antagonized by this temporal increase in Id3 expression, E protein dominance 
is subsequently restored141. RORγt expression in thymocytes is highly specific for DP cells, 
where it works in a different gene network context than it does in mature Th17 cells142, 143. 
In DP cells, it works with Myb to promote viability through BclxL induction while 
suppressing conventional effector responses like proliferation or cytokine production144-146. 
The roles of TCF-1 and LEF-1 may be qualitatively altered at this point by a stage-specific 
interaction with the canonical Wnt pathway mediator β-catenin, which is more strongly 
implicated in effects at β-selection than in earlier stages88, 147-150. This altered regulatory 
factor ensemble turns on the expression of CD4, CD8, CD2 (in mice), and CD28.
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However, arguably the most dramatic feature of the change in the developmental gene 
network at β-selection is repression. Any residual expression of phase 1 genes vanishes 
along with DN3-specific regulatory genes like SpiB and Ahr and the Notch-dependent genes. 
The whole Notch-dependent regulatory framework is dismantled like a redundant assembly 
scaffold (Fig. 3f). The broad downregulation of multiple Notch targets may result from 
repression of Lfng, which disables Notch on DP cells from access to its intrathymic 
ligands71. As cells become DP, H3K27me3 repression marks pile up at the promoters of 
phase 1 genes and Notch targets such as Hes131, 103. The resultant new regulatory state 
prepares DP thymocytes for the complex positive and negative selection events that they 
must undergo.
Although relatively few “new” factors enter the regulatory mix, the β-selection cascade is 
dangerous because of the way new growth signals impinge on a rapidly altering regulatory 
state. Cells with inadequate E protein or Ikaros activity cannot control access to this 
transition or re-establish quiescence correctly, and they become malignantly transformed. 
Notch target genes must be silenced: inappropriately prolonged Notch activity, in the 
context of TCR complex activation during β-selection, tilts the cells toward leukemia. 
Furthermore, as described below, any persistence of phase 1 gene expression through this 
transition can itself lead to leukemic transformation.
T-cell leukemia
Checkpoint failure and T-cell leukemias
The earliest stages of early T-cell development are replete with potent proto-oncogenes (Fig. 
1b; Table 2) inherited from pre-thymic progenitors. Many of these genes encode factors that 
regulate proliferation, survival and differentiation in the earliest stages of T-cell 
development in conjunction with the Notch–mediated T-cell specification program, although 
termination of this progenitor program is imperative for both completing T-cell specification 
and avoiding leukemogenesis. Overexpression of individual phase 1 transcription factors in 
mouse hematopoietic stem and progenitor cells commonly lead to self-renewal and 
transformation, with the specific leukemia type dependent upon the cell in which it is first 
overexpressed (Table 2). In addition, recent data show that if early thymic cells are not 
displaced from their intrathymic niches by new immigrants, they retain self-renewal 
potential coupled with a threat of leukemic transformation 15-17.
Repression of legacy proto-oncogenes occurs at several developmental points (Figure 1). 
While a subset of these genes terminates expression within the ETP stage, others are 
expressed through to the commitment checkpoint, after which time most of these phase 1-
specific genes are repressed. By the time cells transit through the β-selection checkpoint, 
remnants of the stem/progenitor program are fully and permanently extinguished. Epigenetic 
mechanisms likely play important roles in establishing and maintaining repression of the 
progenitor gene programs, although the process needs clarification and likely varies between 
stages and specific genes. For example, progenitor genes that continue to be expressed until 
commitment are generally not strongly marked by H3K27me3 until after β-selection, even 
though most are repressed in the DN2 stage31. These results hint that proliferation may be 
needed for establishment of repressive chromatin.
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T-ALLs in humans are a heterogeneous group of aggressive T-cell malignancies that are 
thought to arise from oncogenic transformation of immature thymocytes151. These 
leukemias can result from mutation and/or uncontrolled activation of a T-cell proto-
oncogene, such as Notch, or from translocation of an exogenous oncogene to the control of 
T-cell specific promoters or enhancers like those of a TCR locus or BCL11B. Sub-types of 
human T-ALL, with differing treatment responses and relapse rates, have been identified 
based on surface phenotypes and genetic signatures, including overexpression of specific 
transcription factors and surface receptors characteristic of different stages of the T-cell 
differentiation program152-156. While these genetic signatures provide hints as to the 
primary and cooperating genetic lesions in the multi-step process that drives malignant 
transformation, manipulatable mouse models are invaluable for investigating the sequence 
of genetic lesions that can initiate and sustain T-ALLs. Although some markers of T-cell 
development differ between humans and mice157, 158, the broader requirements for Notch 
and cytokines, as well as underlying transcriptional networks are very similar159, making 
results with mouse models relevant to human T-ALL.
Failure to transit correctly through the β-selection checkpoint due to sustained Notch 
signaling or loss of E proteins or Ikaros has long been known to result in malignant 
transformation of early T-cells134, 160-162. Constitutively activated Notch signaling is 
particularly potent at triggering T-cell leukemia in both humans and mice, with over 50% of 
human T-ALL cases exhibiting activating mutations in NOTCH1 or its pathway151, 160, 163. 
However, in both mice and humans distinct “early” subtypes of T-ALL exist, with 
characteristics of very immature T-cells, and these may arise from a failure to permanently 
repress legacy phase 1 stem and progenitor genes, which have only recently been recognized 
to be a major part of early T-cell differentiation156.
High expression of phase 1 genes LYL1 and LMO2 was originally found to distinguish 
subtypes of human T-ALLs that are associated with higher rates of treatment failure and 
relapse153. Subsequently, a T-ALL subtype was designated as ETP T-ALL (ETP-ALL), 
based on overexpression of genes expressed by murine thymic ETP cells, including KIT, 
GATA2, CEBPA, SPI1 (PU.1), LYL1, and ERG1, 18. ETP-ALLs also express myeloid surface 
markers and have lower levels of typical T-cell genes. Genome-wide sequencing of human 
ETP-ALLs showed that they commonly have activating mutations in cytokine receptor 
genes (FLT3, IL7R) and genes encoding members of RAS signaling pathways, as well as 
inactivating mutations in some important T-cell genes and specific histone modifying genes, 
and that they resemble myeloid stem cells and acute myeloid leukemia more than other 
forms of T-ALL19. Thus, the genetic characteristics of ETP-ALL, including the genes 
shared with myeloid progenitors, indicate a failure to properly terminate the normal phase 1 
regulatory state, despite the onset of the T-cell specification program. As in murine early T 
cells, the human T-cell development program could be built on a proto-myeloid 
foundation164.
Specific genes involved in epigenetic silencing are mutated in many ETP-ALL, especially 
genes EZH2, SUZ12, and EED19, which are part of the Polycomb Repressive Complex 2 
(PRC2) that mediates H3K27 trimethylation. This further supports a role for these pathways 
in extinguishing expression of stem/progenitor phase 1 genes during normal commitment, as 
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implied by repression marking patterns in mice31. Loss-of-function mutations in 
components of PRC2 are found in other kinds of T-ALLs as well, however, suggesting more 
diverse stage-specific roles in normal T-cell development and tumor suppression165. Other 
genes involved in establishing gene repression, such as the DNA methyltransferase 
DNMT3A, are also mutated in some subsets of T-ALL166, although the role of this gene and 
other epigenetic factors in early T-cell development and leukemia initiation in mice and 
humans have yet to be determined.
Three mouse models provide additional insights into the mechanisms of leukemogenesis due 
to loss of phase 1-specific transcription factor gene repression. First, when overexpressed in 
mouse DN thymocytes, the ETP-specific gene Lmo2 generates a self-renewing population of 
Kithi DN thymocytes, and the mice develop T-cell leukemias after a long latency 
period63, 167. While the frank leukemia probably depends on accumulating additional 
mutations, the preleukemic self-renewing cells already express other phase 1 genes 
including Hhex and Lyl1, which play cooperative roles with Lmo2 in self-renewal and 
leukemogenesis59, 63. Although most T-ALLs also carry activating Notch pathway 
mutations, it is noteworthy that ETP-ALLs need not do so. T-lineage expression of an Lmo2 
transgene induces T-ALL in mice by two distinct pathways: one requires Notch activation 
but the other, ETP-ALL type, requires only the sustained expression of classic phase 1 genes 
Lmo2, Lyl1, Hhex, and Mycn155.
Second, early T cells from Cdkn2a-/- mice could be transformed by retroviral transduction 
with Il7r carrying constitutively activating mutations identified from human ETP-ALLs. The 
cells generated transplantable leukemias resembling human ETP-ALL168, in which myeloid 
potential was combined with an early T-cell phenotype. These mutations blocked cell 
differentiation at an uncommitted DN2a-like stage, and the leukemic cells themselves 
showed high levels of Lmo2, low to undetectable levels of Bcl11b, and most did not have 
activating Notch mutations. This mouse model shows that abnormal cytokine receptor 
signals can prevent or reverse Lmo2 silencing, Bcl11b upregulation and T lineage 
commitment and that this can efficiently lead to transformation.
Third, Rag-deficient NOD mice also exhibit spontaneous emergence of an aberrant self-
renewing thymocyte population from the DN2 stage. These mice also develop T-cell 
leukemias with high penetrance, which share some gene expression features with human 
ETP-ALL169, 170. These abnormal thymocytes emerge from the DN2 stage as Kithi cells that 
fail to repress many of the phase 1-specific genes including Lmo2, Lyl1, Hhex, and Mef2c. 
These emerging cells also continue some aspects of the T-cell program by activating genes 
characteristic of committed DN3 cells, like Ptcra, and Spib. However, they bypass the β-
selection checkpoint even without TCR gene rearrangements and aberrantly turn on Cd4, 
Cd8, and Cd5. Thus, this model provides additional evidence that failure to repress the stem/
progenitor program at the commitment checkpoint can initiate T-cell transformation. 
Furthermore, transformation at this checkpoint does not necessarily preclude aberrant 
activation of some aspects of the T-cell differentiation program.
Taken together, these studies of mouse and human T-ALL suggest that a breakdown of 
repressive mechanisms normally enforced at the commitment and β-selection checkpoints 
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can lead to specific forms of T-ALL. A more complete understanding of epigenetic and 
checkpoint control mechanisms in normal T-cell development may shed light on leukemia 
initiation and subsequent transformational events leading to generation of leukemia stem 
cells.
Conclusions
The T cell commitment program is not a simple cumulative progression toward endowment 
of T-cell character, but rather a series of distinct regulatory phases with different, sometimes 
mutually antagonistic features (Figure 3). An initial phase of proliferative expansion in 
which differentiation is actively deferred is important to establish an adequate pool of cells, 
and it is this phase 1 developmental program that is “tuned” to promote varying numbers of 
cell divisions according to the needs of fetal and postnatal T-cell development. At least some 
of the stem- and progenitor-cell factors needed to sustain this phase are incompatible with T-
lineage commitment and must be repressed. The lasting features of the commitment process 
include the irreversibility of silencing of phase 1 factors. The commitment process 
establishes a growth-limited state dominated by different transcription factors, at least one of 
which, Bcl11b, is only turned on at commitment. Other features (like intensified Notch 
signaling) are normally temporary, until cells acquire a pre-TCR or γδ TCR, allowing them 
to exit the commitment process and pass into a third phase. The effective termination of 
each phase as the cells transition to the next can be viewed as the cells’ vital bulwark against 
malignant transformation. Failure to terminate the phase 2 program as the cells pass through 
β-selection, i.e. by continuing Notch activity, has long been recognized to contribute to T-
ALL. It is now clear that particularly severe forms of T-ALL are those in which the phase 1–
2 transition is porous or too easily re-crossed. Thus, the early lineage commitment events, 
occurring in only a tiny fraction of cells in the steady-state thymus at any given time, not 
only offer an illuminating paradigm for developmental fate determination but also take on 
extreme significance for the fate of the organism as a whole.
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Key Terms
Commitment Stage when cells give up any intrinsic capability to give rise to more 
than one kind of descendant. This concept depends on recognizing 
that precursor cells often begin with intrinsic potential to give rise to a 
variety of different types of descendants. In embryology and 
hematopoiesis, the actual choices of fates such precursor cells adopt 
will be different, depending on signals they receive from the 
environment. Commitment is the developmental transition within a 
given pathway during which the cells’ choice of fate becomes 
intrinsically irreversible, independent of the environment
Notch signalling A signalling system comprising highly conserved transmembrane 
receptors that regulate cell-fate choice in the development of many 
cell lineages, and so are vital in the regulation of embryonic 
differentiation and development. Unusually among signaling systems, 
the cytoplasmic domain of each Notch transmembrane protein can 
itself become a transcriptional coactivator in the nucleus, because it is 
proteolytically cleaved from the transmembrane region when Notch 
interacts with its ligands of the Delta or Jagged family
T-cell acute 
lymphoblastic 
leukemias
Leukemias with an immature T cell phenotype
Common 
Lymphoid 
Progenitor
(CLP). A progenitor cell type that appears to be committed to 
lymphoid fates as measured by in vivo transfer, and that can give rise 
to all lymphocyte cell types, including T cells, B cells and natural 
killer cells
Lymphoid-
primed 
Multipotent 
Precursor
(LMPP) A multilineage precursor cell type that can generate myeloid 
as well as lymphoid descendants in vivo and in vitro, but not 
erythroid or megakaryocytic cells
Positive 
selection
A step in the process of T-cell differentiation in the thymus that 
selects CD4+CD8+ double-positive T cells for survival and 
maturation, based on the appropriate degree of interaction between 
their T-cell receptor and peptide–MHC complexes on thymic 
epithelial cells. Depending on the class of MHC molecule recognized, 
thymocytes are positively selected either to a CD4+ or to a CD8+ 
single-positive cell fate
Gene regulatory 
network
A system of relationships among a set of regulatory factor coding 
genes and the transcription factors that are their products, defined and 
understood such that the interactions between them explain the 
stability or change in the developmental properties of a cell type that 
expresses these genes
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Pioneer Factor A transcription factor that has the ability to bind to its target site even 
when the site is initially engaged in nucleosome-packed chromatin, 
serving as a focal point for recruitment of other transcription factors; 
crucial for the multi-step process needed to activate some positive 
regulatory elements in the genome during development
WNT A signalling mediator named both for its mutant phenotype in 
Drosophila melanogaster (Wingless) and for its role as a preferential 
retrovirus integration site in murine leukaemia virus-induced 
leukaemias (Int-1). WNT signalling activates the TCF1 and LEF1 
family transcription factors through stabilizing their co-activator, β-
catenin, and mobilizing it from the cytoplasm to the nucleus
ChIP-seq 
analysis
A genome-wide method of mapping the sites where a transcription 
factor is binding to the DNA in a cell, based on cross-linking proteins 
to chromatin, immune-precipitating the chromatin with antibodies to 
the factor of interest, comprehensively sequencing the DNA that is 
recovered in the immune precipitates, and aligning it to the genome to 
identify the enriched regions
Non-obese 
diabetic (NOD) 
mice
NOD mice spontaneously develop type 1 diabetes mellitus as a result 
of autoreactive T-cell-mediated destruction of pancreatic beta-islet 
cells
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Box 1
γδ T-Cell Development Overview
Two classes of T cells expressing distinct TCR dimers, αβ and γδ, have been maintained 
in all jawed vertebrate taxa since TCR-expressing cells first evolved171. γδ T-cells share 
common intrathymic precursors with αβ T-cells, but undergo different differentiation 
programs following TCR expression172. Successful assembly of a γδTCR triggers signals 
that lead to down-regulation of CD25; however, γδTCR+ cells proliferate much less than 
pre-TCR+ cells and do not turn on CD4 or CD8. Specific characteristics of individual 
precursor cells at different stages may bias them towards the γδ- or αβ-lineage. DN2 cells 
in general, particularly those with high levels of IL7R and/or Sox13, can frequently adopt 
a γδ fate, but individual DN3a cells are more likely to produce αβ T-cells38, 173-175 (Fig. 
2). Interplay of Notch signals with signals from the newly expressed pre-TCR or γδTCR 
is important for αβ vs. γδ divergence, although the outcomes of this interaction differ 
between mouse and human176. A γδTCR can produce a stronger signal than a pre-TCR, 
leading to more intense upregulation of Id3 and Erg, and initiation of a γδ rather than an 
αβ T-cell program177, 178.
Interestingly, γδTCR signaling triggers one of several different genetic programs 
available for γδTCR-expressing cells, differentially depending upon Id3, Sox13, Zbtb16 
(encoding PLZF), and/or Bcl11b for further development and effector 
functions127, 130, 174, 179-181. The range of accessible γδ-subtype fates narrows with 
differentiation from DN2a to DN3a130. These γδ–lineage-specific programs mirror the 
range of Th1, Th2, NKT and Th17 effector programs that αβ T-cells acquire at later 
stages, either after positive selection or in the periphery. However, γδ T-cells can 
implement specific effector programs directly upon first TCR expression and signaling 
within the thymus. Unlike αβ T-cells, these functions correlate with particular TCRγ and 
δ segment usages179(see reviews172, 182, 183).
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Box 2
Mechanisms of Alternative Lineage Exclusion
CLPs and LMPPs retain the potential to generate diverse lymphocyte types, as well as 
natural killer, dendritic, and myeloid cells under somewhat different ranges of permissive 
conditions 21-23, 52. Contact with the thymic environment efficiently blocks the cells’ 
access to these non-T cell lineage potentials through a variety of mechanisms, however, 
and under normal conditions the overwhelming majority of precursors only generate T 
cells in situ184, 185. Nevertheless, a gene network state providing latent competence to 
switch to other fates persists throughout the first few stages of T-cell development, which 
can be detected by experimentally removing the cells from the normal thymus. 
Alternative lineage potentials are lost at different times (Fig. 2) and by at least three 
different mechanisms. At the earliest thymic stage, as ETP cells turn off Flt3 expression, 
they unconditionally lose their B-cell potential100, 125, 126. The mechanism depends on 
Notch signals and GATA-397, 186, but this remains incompletely defined21, 99, 187.
Exclusion of myeloid and dendritic cell potentials is caused by removal of a positive 
regulator. Access to both options correlates with the expression profile of PU.1, and at 
early stages C/EBP factors, present at low levels, may also contribute188, 189. But while 
PU.1 is present Notch signaling keeps myeloid options under check. First, Notch-induced 
Hes1 represses Cebpa75. Notch signaling also modulates the spectrum of PU.1 
transcriptional activities irrespective of C/EBPα66, 188, 190. PU.1 is silenced during 
DN2b, under the influence of Runx and possibly TCF-1 or GATA-329, 191-193 as well, 
closing the myeloid options.
The loss of access to NK and ILC2 fates may instead be due to activation of a repressor, 
i.e. activation of Bcl11b. Both innate lymphocyte programs require Id2 in order to 
neutralize E protein activity, and Bcl11b is implicated directly in keeping Id2 
silent117, 118, 122.
Ironically, essential T-cell lineage regulatory inputs may themselves represent a threat for 
alternative lineage diversion during the uncommitted stages of T-cell development if 
their levels are dysregulated. Overexpression of GATA-3 can drive the cells toward a 
mast-cell fate29, antagonizing Notch-dependent survival systems. GATA-3 and TCF-1 
can also work in a low-E protein regulatory state to promote development to 
ILC2s30, 194, 195 instead of T cells, and even excessive Notch signals may favor ILC fates 
in human precursors196. These alternatives too are removed during the commitment 
transition, through mechanisms that need to be clarified.
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Figure 1. αβT-cell development: stages, surface markers, and transcription factor expression
a. Adult mouse T-cell development begins in the bone marrow from lymphoid-primed 
prethymic progenitors that migrate to the thymus and begin differentiation in the thymic 
environment, which provides Notch ligands (blue arrows). Cells transit sequentially through 
DN1/ETP, DN2a, DN2b, DN3a, DN3b, DN4, and DP stages on the way to becoming αβT-
cells (DN: CD4- CD8-; DP: CD4+ CD8+; ISP transitional-stage cells not shown). DN1 
(CD44+ CD25-) cells include a subset with high Kit expression that contains the Early T-cell 
Precursors (ETP; CD44+Kit++CD25-), which contain essentially all the T-cell progenitor 
activity and are the only kind of DN1 cells that will be considered further here. ETPs lack or 
have downregulated IL7R, but as they differentiate to DN2, they turn on IL7R. Key cell 
surface receptors used to identify these stages are shown indicating the stages during which 
each receptor is expressed. Dotted lines indicate stages with lower expression levels. The 
stages during which TCR rearrangements occur are also marked. Development is divided by 
the commitment and β-selection checkpoints into three major regulatory phases (Phases 1, 2, 
and 3: post-β-selection), each with unique gene networks and cellular characteristics. Cells 
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in phase 1 proliferate extensively and retain multipotentiality, while phase 2 cells are 
committed, slow their proliferation, and undergo TCR rearrangements. Only cells with a 
rearranged TCRβ that can combine with pre-Tα and transduce a signal can continue through 
the β-selection checkpoint into phase 3, a second highly proliferative but increasingly 
Notch-independent phase leading to CD4 and CD8 upregulation, then proliferative arrest, 
and TCRα rearrangement.
b. Stage-specific patterns of expression of important transcription factor genes are shown 
below the developmental stages. The color intensity variations provide an approximation of 
the dynamic changes in expression of the genes, grouped together based on similar 
expression patterns although not necessarily similar levels; for more accurate quantitation of 
gene expression, see sources of this figure in Zhang et al.31 and ImmGen32, 197 
(www.immgen.org). The transcription factor genes are divided into legacy stem and 
progenitor genes that are mostly turned off in Phase 1 and are all off by β-selection (blue 
bars), and genes that are critical to different aspects of the T-cell specification and 
commitment programs (red bars). Additional information about each of these genes is 
provided in Tables 1 and 2.
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Figure 2. T-lineage commitment and alternative lineage potentials
Diagram of early T-cell development for αβT-cells from bone marrow prethymic 
progenitors to entry into and development in the thymus, showing the stages from which 
alternative lineages can develop. The figure shows which fates can be accessed by cells in 
the presence of Notch signaling (upward pointing arrows), including γδT-lineage cells that 
can develop from DN2a/b and DN3 cells (brown arrows), as well as those fates that can only 
be accessed by experimental withdrawal from Notch signaling (downward pointing arrows). 
Arrows shown emerging from the thymus show conditional outcomes usually only observed 
if the cells are removed from the thymic environment. Alternative non-T-lineage innate 
lymphocytes (ILC2) can be generated from bone marrow precursors, as well as ETP and 
DN2 cells, but only in the presence of Notch ligands and specific cytokines. In the absence 
of Notch ligands, B-cells can be generated from bone marrow precursors and a subset of the 
earliest (Flt3+) ETP cells, while dendritic cells (DC) and granulocytes (Gr) or macrophages 
(Mac), can be derived from prethymic progenitors as well as from thymic ETP cells and to a 
lesser extent from DN2a cells, but not from later stage cells. Natural killer (NK) cells also 
develop well from prethymic, ETP and DN2a cells, but not from later stage cells. Broken-
line arrows denote potentials seen in low-frequency precursors within a population. Shown 
also are some key transcription factors that are critical for specific transitions (see text and 
Fig. 3).
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Figure 3. Progression of gene regulatory network states in T-cell commitment: current model
Panels a-f (clockwise progression) show a model of the sequential changes in regulatory 
relationships between the genes, based on evidence discussed in the text, from the early 
Flt3+ ETP stage (a) through commitment (c-d) to β-selection (f). Passage through the 
indicated changes in gene network states (a-f) occurs during periods that correspond 
approximately to developmental stages, as defined by cell-surface markers, which are 
indicated at the top of each panel, but the regulatory states may not be homogeneously 
equivalent to these stages. Phase 1: panels a, b. Transition to phase 2: panel c. Phase 2: 
panels d, e, in which panel d emphasizes the regulatory gene expression changes and panel E 
emphasizes the consequences of those changes. Phase 3, post β-selection (for αβT lineage): 
panel f. Boxes enclose genes that operate coordinately at a given stage even if the details of 
regulation that link them are not known. Arrows indicate activation. Lines ending in bars 
indicate repression. Dashed lines indicate “soft repression” which limits the maximal 
activity or deployment of a transcription factor but does not silence its expression. Dotted 
lines: likely but undemonstrated linkages. Faded colors: decreasing expression or functional 
impact of a given gene or gene group as a result of regulatory effects shown elsewhere in the 
panel. (Id2), potential for activation of Id2 in response to cytokine signaling or other stimuli, 
which is held in check by Bcl11b. Note that E2A/HEB heterodimers can play a positive role 
in Gata3 and Tcf7 induction as well as exerting restraint on maximum levels of Gata3 
expression. TCR recombination and assembly genes steeply increase in expression from 
DN2a to DN3a, but are most functionally significant in DN3a. As revealed by T-ALL 
phenotypes, cells that take a “short cut” from the states represented in panels a-b to the 
activation events in panel f, bypassing the commitment process, are susceptible to oncogenic 
transformation. For details, see text.
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Table 1
Critical T-cell specification transcription factor genes in murine early T-cells and their 
progenitors
Gene Gene Family Knockout phenotype Overexpression phenotype Selected References
Notch1 NOTCH, ankyrin repeat Block in T development T-ALL 1-3 Reviewed in 4, 5
Runx1 (AML1) RUNT
Early stem cell defects; Block 
before DN3; Myeloproliferation AML 6 7
Ets1 ETS
Impaired DN3 to DP 
development and allelic 
exclusion; Defective NK and 
CD8 cell development 8, 9 10
Ikzf1 (IKAROS) IKAROS C2H2 ZnF
Loss of lymphoid cells and 
progenitors; T- and B-ALL 11, 12
Tcf3 (E2A)
E protein basic helix-
loop-helix (bHLH)
Defects in hematopoietic stem 
cell pools; DN2 defects; T-ALL
13, 14
 Reviewed in 
15
Myb
MYB SANT (helix-turn-
helix, HTH) Multiple blocks from HSC to DP 16-19
Myc (c-myc) MYC bHLH
Defects in proliferation and 
survival of HSC, lymphoid 
progenitors, after β-selection T-ALL 20-22
Tcf7 (TCF1) TCF HMG
Almost complete loss of T cell 
development; T-ALL
Limited T development in 
the absence of Notch signals 23-26 27
Gata3 GATA ZnF
No DN cells; if deleted later, β-
selection block and loss of CD4 
cells
Poor viability, diversion to 
mast cells
28, 29
 Reviewed in 
30
 
31
Hes1 HAIRY bHLH Defective T-cell development 32, 33 34
Bcl11b (CTIP2) ZnF, C2H2-like
No αβ T cells; Accumulation of 
DN2a and NK cells 35, 36 37, 38
Tcf12 (HEBcan/alt) E protein bHLH
Partial developmental blocks at 
DN1 and between DN3 and DP
Enhanced T-cell 
differentiation, reduced 
proliferation (esp. HEBcan) 39 Reviewed in 40
Lef1 TCF HMG
No phenotype alone; ISP block 
with hypomorphic Tcf7 T-ALL 26, 41
Gfi1 SNAG, C2H2-like ZnF
Partial block between ETP and 
DN2 Potentiates T-ALL 42, 43
bHLH, basic helix-loop-helix; C2H2, Cys2 His2, a form of Zinc finger; ETS, E26 transformation-specific; HMG, high mobility group; HTH, helix 
turn helix; SNAG, Snail/Gfi1 domain, a repression domain; Znf, zinc finger
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